Targeting the integrin VLA-4 with natalizumab has shown efficacy in treating multiple sclerosis, but relapse still occurs in some patients. Here the authors use a high-content cell imaging (HCI) pipeline and machine learning to assess the morphology of T cells from MS patients prior to natalizumab regime for defining features associated with treatment responses.
- Beatriz Chaves
- Juan Carlo Santos e Silva
- Loïc Dupré
